

**p63 antibody**  
**Purified Rabbit Polyclonal Antibody (Pab)**  
**Catalog # AP22479a**

**Specification**

---

**p63 antibody - Product Information**

Application	WB,E
Primary Accession	<a href="#">Q9H3D4</a>
Reactivity	Human
Host	Rabbit
Clonality	polyclonal
Isotype	Rabbit Ig
Calculated MW	76785

**p63 antibody - Additional Information**

**Gene ID** 8626

**Other Names**

Tumor protein 63, p63, Chronic ulcerative stomatitis protein, CUSP, Keratinocyte transcription factor KET, Transformation-related protein 63, TP63, Tumor protein p73-like, p73L, p40, p51, TP63, KET, P63, P73H, P73L, TP73L

**Target/Specificity**

This antibody is generated from a rabbit immunized with a KLH conjugated synthetic peptide between amino acids from human.

**Dilution**

WB~~1:1000

E~~Use at an assay dependent concentration.

**Format**

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

**Storage**

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

**Precautions**

p63 antibody is for research use only and not for use in diagnostic or therapeutic procedures.

**p63 antibody - Protein Information**

**Name** TP63

**Synonyms** KET, P63, P73H, P73L, TP73L

**Function** Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA\*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter.

#### **Cellular Location**

Nucleus

#### **Tissue Location**

Widely expressed, notably in heart, kidney, placenta, prostate, skeletal muscle, testis and thymus, although the precise isoform varies according to tissue type. Progenitor cell layers of skin, breast, eye and prostate express high levels of DeltaN-type isoforms. Isoform 10 is predominantly expressed in skin squamous cell carcinomas, but not in normal skin tissues

### **p63 antibody - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

### **p63 antibody - Images**

### **p63 antibody - Background**

Acts as a sequence specific DNA binding transcriptional activator or repressor. The isoforms contain a varying set of transactivation and auto-regulating transactivation inhibiting domains thus showing an isoform specific activity. Isoform 2 activates RIPK4 transcription. May be required in conjunction with TP73/p73 for initiation of p53/TP53 dependent apoptosis in response to genotoxic insults and the presence of activated oncogenes. Involved in Notch signaling by probably inducing JAG1 and JAG2. Plays a role in the regulation of epithelial morphogenesis. The ratio of DeltaN-type and TA\*-type isoforms may govern the maintenance of epithelial stem cell compartments and regulate the initiation of epithelial stratification from the undifferentiated embryonal ectoderm. Required for limb formation from the apical ectodermal ridge. Activates transcription of the p21 promoter.

### **p63 antibody - References**

Senoo M., et al. Biochem. Biophys. Res. Commun. 248:603-607(1998).  
Augustin M., et al. Mamm. Genome 9:899-902(1998).  
Yang A., et al. Mol. Cell 2:305-316(1998).  
Osada M., et al. Nat. Med. 4:839-843(1998).  
Hagiwara K., et al. Cancer Res. 59:4165-4169(1999).